BioReliance Adds Advanced In-Vitro ADME and Toxicology Services
BioReliance has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services its service offering. The company?s range of predictive assays use a novel suite of genetically modified cell lines created with CompoZr zinc finger nuclease (ZFN), a Sigma-Aldrich proprietary technology.
BioReliance, Sigma-Aldrich Corporation’s biologics and early-development services business, announced that it has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services its service offering. The company’s range of predictive assays use a novel suite of genetically modified cell lines created with CompoZr zinc finger nuclease (ZFN), a Sigma-Aldrich proprietary technology.
“The new in vitro ADME and toxicology testing services complement the existing genetic toxicology testing portfolio at BioReliance, and have been designed to meet the growing demand for more predictive human cell-based assays,” said Daniel Aparicio, executive director and general manager of Toxicology at BioReliance, in a press release.
Developed in line with FDA, EMA and ITC guidelines, the assays enables evaluation of a drug product’s permeability, transport, metabolism and toxicity. Each cell line is tested for functionality, allowing drug discovery scientists to isolate any compounds that may affect product development before it can affect the safety or efficacy of a possible drug product.
More information about BioReliance’s in vitro ADME and toxicology testing services can be found here.
Source: BioReliance
